(CLDX) Celldex Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US15117B2025

Antibody, Vaccine, Cancer

CLDX EPS (Earnings per Share)

EPS (Earnings per Share) of CLDX over the last years for every Quarter: "2020-09-30": -0.36, "2020-12-31": -0.55, "2021-03-31": -0.42, "2021-06-30": -0.34, "2021-09-30": -0.45, "2021-12-31": -0.43, "2022-03-31": -0.49, "2022-06-30": -0.59, "2022-09-30": -0.57, "2022-12-31": -0.56, "2023-03-31": -0.62, "2023-06-30": -0.65, "2023-09-30": -0.81, "2023-12-31": -0.83, "2024-03-31": -0.56, "2024-06-30": -0.54, "2024-09-30": -0.64, "2024-12-31": -0.71, "2025-03-31": -0.81, "2025-06-30": -0.85,

CLDX Revenue

Revenue of CLDX over the last years for every Quarter: 2020-09-30: 0.668, 2020-12-31: 3.786, 2021-03-31: 0.685, 2021-06-30: 3.48, 2021-09-30: 0.153, 2021-12-31: 0.333, 2022-03-31: 0.174, 2022-06-30: 0.163, 2022-09-30: 0.407, 2022-12-31: 1.613, 2023-03-31: 0.967, 2023-06-30: 0.268, 2023-09-30: 1.517, 2023-12-31: 4.131, 2024-03-31: 0.156, 2024-06-30: 2.498, 2024-09-30: 3.191, 2024-12-31: 1.175, 2025-03-31: 0.695, 2025-06-30: 0.73,

Description: CLDX Celldex Therapeutics

Celldex Therapeutics Inc (NASDAQ:CLDX) is a biotechnology company listed on the NASDAQ stock exchange, operating in the biotechnology sub-industry. The companys stock is characterized by high volatility, as indicated by its beta of 1.223, suggesting that its stock price is more volatile than the overall market.

The stocks recent price movement shows a current price of $20.01, below its short-term and long-term moving averages, indicating a potential downtrend. The Average True Range (ATR) of 1.16 represents a 5.77% daily price range, highlighting the stocks volatility. With an average trading volume of 865,236 shares, the stock has sufficient liquidity.

From a fundamental perspective, Celldex Therapeutics has a market capitalization of $1.37 billion, indicating a mid-cap company. The absence of a Price-to-Earnings (P/E) ratio and a negative Return on Equity (RoE) of -27.62% suggests that the company is currently unprofitable. Key economic drivers for the companys stock performance include progress in its clinical trials, regulatory approvals, and the overall demand for its products or services.

To evaluate the companys potential, key performance indicators (KPIs) such as revenue growth, cash burn rate, and the advancement of its pipeline products are crucial. Investors should also consider the competitive landscape, managements track record, and the overall outlook for the biotechnology sector. A thorough analysis of these factors can help investors make informed decisions about investing in Celldex Therapeutics.

CLDX Stock Overview

Market Cap in USD 1,513m
Sub-Industry Biotechnology
IPO / Inception 2008-03-10

CLDX Stock Ratings

Growth Rating -36.1%
Fundamental 24.5%
Dividend Rating -
Return 12m vs S&P 500 -50.0%
Analyst Rating 4.57 of 5

CLDX Dividends

Currently no dividends paid

CLDX Growth Ratios

Growth Correlation 3m 56.5%
Growth Correlation 12m -61.2%
Growth Correlation 5y -7.3%
CAGR 5y -5.59%
CAGR/Max DD 3y -0.08
CAGR/Mean DD 3y -0.17
Sharpe Ratio 12m -2.11
Alpha 0.06
Beta 0.738
Volatility 50.64%
Current Volume 1247.2k
Average Volume 20d 1385.5k
Stop Loss 23 (-6%)
Signal -0.29

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-199.6m TTM) > 0 and > 6% of Revenue (6% = 347.5k TTM)
FCFTA -0.23 (>2.0%) and ΔFCFTA -10.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 10.6k% (prev 9447 %; Δ 1180 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.27 (>3.0%) and CFO -186.2m > Net Income -199.6m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 19.67 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (66.4m) change vs 12m ago 0.56% (target <= -2.0% for YES)
Gross Margin 72.28% (prev 62.68%; Δ 9.60pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.75% (prev 0.98%; Δ -0.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

Altman Z'' -51.23

(A) 0.89 = (Total Current Assets 648.4m - Total Current Liabilities 33.0m) / Total Assets 692.4m
(B) -2.41 = Retained Earnings (Balance) -1.67b / Total Assets 692.4m
warn (B) unusual magnitude: -2.41 — check mapping/units
(C) -0.31 = EBIT TTM -234.7m / Avg Total Assets 769.0m
(D) -44.92 = Book Value of Equity -1.66b / Total Liabilities 37.0m
Total Rating: -51.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 24.45

1. Piotroski 1.0pt = -4.0
2. FCF Yield -17.98% = -5.0
3. FCF Margin data missing
4. Debt/Equity 0.01 = 2.50
5. Debt/Ebitda -0.02 = -2.50
6. ROIC - WACC (= -32.48)% = -12.50
7. RoE -27.62% = -2.50
8. Rev. Trend 13.73% = 1.03
9. EPS Trend -51.59% = -2.58

What is the price of CLDX shares?

As of September 18, 2025, the stock is trading at USD 24.46 with a total of 1,247,152 shares traded.
Over the past week, the price has changed by -2.00%, over one month by -0.08%, over three months by +21.93% and over the past year by -40.69%.

Is Celldex Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Celldex Therapeutics (NASDAQ:CLDX) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 24.45 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CLDX is around 20.73 USD . This means that CLDX is currently overvalued and has a potential downside of -15.25%.

Is CLDX a buy, sell or hold?

Celldex Therapeutics has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy CLDX.
  • Strong Buy: 10
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CLDX price?

Issuer Target Up/Down from current
Wallstreet Target Price 55.6 127.4%
Analysts Target Price 55.6 127.4%
ValueRay Target Price 23.2 -5.3%

Last update: 2025-09-05 04:37

CLDX Fundamental Data Overview

Market Cap USD = 1.51b (1.51b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 630.3m USD (Cash And Short Term Investments, last quarter)
P/S = 261.2677
P/B = 2.3922
Beta = 1.193
Revenue TTM = 5.79m USD
EBIT TTM = -234.7m USD
EBITDA TTM = -231.4m USD
Long Term Debt = 4.04m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.54m USD (from shortTermDebt, last quarter)
Debt = 5.57m USD (Calculated: Short Term 1.54m + Long Term 4.04m)
Net Debt = -20.0m USD (from netDebt column, last quarter)
Enterprise Value = 888.0m USD (1.51b + Debt 5.57m - CCE 630.3m)
Interest Coverage Ratio = unknown (Ebit TTM -234.7m / Interest Expense TTM 0.0)
FCF Yield = -17.98% (FCF TTM -159.7m / Enterprise Value 888.0m)
FCF Margin = -2758 % (FCF TTM -159.7m / Revenue TTM 5.79m)
Net Margin = -3447 % (Net Income TTM -199.6m / Revenue TTM 5.79m)
Gross Margin = 72.28% ((Revenue TTM 5.79m - Cost of Revenue TTM 1.60m) / Revenue TTM)
Tobins Q-Ratio = -0.53 (set to none) (Enterprise Value 888.0m / Book Value Of Equity -1.66b)
Interest Expense / Debt = 55.79% (Interest Expense 3.11m / Debt 5.57m)
Taxrate = 21.0% (US default)
NOPAT = -234.7m (EBIT -234.7m, no tax applied on loss)
Current Ratio = 19.67 (Total Current Assets 648.4m / Total Current Liabilities 33.0m)
Debt / Equity = 0.01 (Debt 5.57m / last Quarter total Stockholder Equity 655.4m)
Debt / EBITDA = -0.02 (Net Debt -20.0m / EBITDA -231.4m)
Debt / FCF = -0.03 (Debt 5.57m / FCF TTM -159.7m)
Total Stockholder Equity = 722.8m (last 4 quarters mean)
RoA = -28.83% (Net Income -199.6m, Total Assets 692.4m )
RoE = -27.62% (Net Income TTM -199.6m / Total Stockholder Equity 722.8m)
RoCE = -32.30% (Ebit -234.7m / (Equity 722.8m + L.T.Debt 4.04m))
RoIC = -32.48% (NOPAT -234.7m / Invested Capital 722.8m)
WACC = unknown (E(1.51b)/V(1.52b) * Re(8.73%)) + (D(5.57m)/V(1.52b) * Rd(none%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 3.21%
Discount Rate = 8.73% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -159.7m)
EPS Correlation: -51.59 | EPS CAGR: -45.62% | SUE: 0.11 | # QB: 0
Revenue Correlation: 13.73 | Revenue CAGR: 23.67% | SUE: -0.36 | # QB: 0

Additional Sources for CLDX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle